Ramasastry Saira 4

What Happened

• Saira Ramasastry, a director of Mirum Pharmaceuticals (MIRM), exercised stock options and sold shares on May 15, 2026. She exercised 2,000 options at $23.51 per share (cost $47,020) and sold 2,000 shares in the open market at $109.47 per share (gross proceeds $218,940). The filing also lists a 2,000-share derivative disposition reported at $0.00.
• Net proceeds before taxes and fees (gross sale proceeds minus exercise cost) are approximately $171,920. The sale was reported as occurring under a Rule 10b5-1 plan.

Key Details

• Transaction date: 2026-05-15; Exercise: 2,000 shares @ $23.51 = $47,020 (Code M, acquired); Sale: 2,000 shares @ $109.47 = $218,940 (Code S, disposed); Derivative disposition: 2,000 shares @ $0.00 (Code M, disposed).
• Footnotes: F1 — sale occurred pursuant to a Rule 10b5-1 plan adopted Sept 18, 2025. F2 — the stock option was fully vested.
• Shares owned after transaction: not specified in this Form 4 filing.
• Filing date: 2026-05-18 for transactions on 2026-05-15 (filing timeliness not flagged in the provided data).

Context

• This sequence (option exercise followed by an immediate sale of the same number of shares) is consistent with exercising vested options and selling shares the same day (often to cover costs or monetize gains). The separate derivative line at $0.00 reflects reporting of the option conversion/settlement; the filing does not provide additional detail about withholding or net-share settlement.
• The sale was executed under a pre-established Rule 10b5-1 plan (per F1), which typically means the trades followed a predetermined schedule rather than ad-hoc trading decisions.